About DICOT

Founded: 2015
Employees: 4
CEO: Elin Trampe
WebsiteView website: www.dicotpharma.com

Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.

Recent DICOT News & Updates

New Risk • May 20

New major risk - Share price stability

The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr78m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (kr462.1m market cap, or US$49.2m).

Recent updates

No updates

Dicot Pharma AB Stock Price

DICOT Share Price Performance

DICOT Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Dicot Pharma AB Key Details

About DICOT

Recent DICOT News & Updates

Insufficient new directors

New major risk - Share price stability

Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?

Recent updates

Dicot Pharma AB Competitors

Vitrolife

BioGaia

MedCap

Swedencare